Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 3, 2024
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
Li Watsek Reiterated (ASND) at Buy and Held Target at $173 on, May 3rd, 2024
Li Watsek of Cantor Fitzgerald, Reiterated "Ascendis Pharma A/S" (ASND) at Buy and Held Target at $173 on, May 3rd, 2024.
Li has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with Li's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold and Held Target at $116 on, Monday, April 22nd, 2024
These are the ratings of the 2 analyists that currently disagree with Li
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $225 on, Thursday, February 8th, 2024
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $182 on, Thursday, February 8th, 2024
